Indeed, in colorectal cancer, one study demonstrated that epigenetic silencing of WRN was associated with improved survival in patients treated with a topoisomerase inhibitor, while another study was not able to validate these findings (Agrelo et al., 2006; Bosch et al., 2016). The gene discussed is WRN; the disease is colorectal cancer.